Lv1
40 积分 2024-04-09 加入
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
2天前
已完结
EfficacyandSafetyofSubcutaneousAnifrolumabinSystemicLupusErythematosus:theRandomizedPhase3TULIP-SCStudy
14天前
已完结
Discovery of Small Molecule Interleukin 17A Inhibitors with Novel Binding Mode and Stoichiometry: Optimization of DNA-Encoded Chemical Library Hits to In Vivo Active Compounds
19天前
已完结
Small molecule interleukin (IL) 17A/A antagonists and antibodies blocking both IL17A/A and IL17A/F demonstrate equivalent degrees of efficacy in preclinical models of skin and joint inflammation
19天前
已完结
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial
29天前
已完结
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
1个月前
已完结
Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus
1个月前
已完结
CAR T-cell therapy in SLE: A systematic review
1个月前
已完结
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
1个月前
已完结
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
1个月前
已完结
皖公网安备34019202002308
